Skip to main content
Erschienen in: World Journal of Surgery 5/2011

01.05.2011

Clinicopathological Features and Outcomes of Young Patients with Hepatocellular Carcinoma after Hepatectomy

verfasst von: Kazuki Takeishi, Ken Shirabe, Jun Muto, Takeo Toshima, Akinobu Taketomi, Yoshihiko Maehara

Erschienen in: World Journal of Surgery | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

There are few reports about hepatectomy for young patients with hepatocellular carcinoma (HCC), and the significance of resection for young patients remains unknown. The present study aimed to investigate retrospectively the clinicopathological features and outcomes after hepatectomy of young HCC patients.

Methods

Among 610 patients who underwent curative hepatectomy for HCC between January 1987 and December 2007, 13 patients younger than 40 years of age were defined as the young group. Because none of the young group had hepatitis C virus antibodies (HCVAb), 246 patients aged above 40 years without HCVAb were defined as the older group. The clinicopathological findings and outcomes after hepatectomy were compared between the two groups.

Results

In the young group, 7 patients had hepatitis B surface antigen and 3 other patients had hepatitis B core antibodies. The young group had better liver function but more advanced HCC, with a large tumor size and a high incidence of portal vein invasion compared with the older group. Major hepatectomy was more frequently chosen in the young group than in the older group. There was no significant difference in the incidences of postoperative complications. The overall survival tended to be better in the young group than in the older group (p = 0.057).

Conclusions

Hepatitis B virus-related HCC was common inthe younger group of patients reported here. Although the young patients had advanced HCC, there were no significant differences in the complication rate and the overall survival rate of the young and older groups. Aggressive hepatic resection for young patients would contribute to improved survival and should be recommended.
Literatur
1.
Zurück zum Zitat El-serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72–S78PubMedCrossRef El-serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35:S72–S78PubMedCrossRef
2.
3.
Zurück zum Zitat Shiratori Y, Yoshida H, Omata M (2001) Different clinicopathological features of hepatocellular carcinoma in relation to causative agents. J Gastroenterol 36:73–78PubMedCrossRef Shiratori Y, Yoshida H, Omata M (2001) Different clinicopathological features of hepatocellular carcinoma in relation to causative agents. J Gastroenterol 36:73–78PubMedCrossRef
4.
Zurück zum Zitat Kiyosawa K, Uemura T, Ichijo T et al (2004) Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127:S17–S26PubMedCrossRef Kiyosawa K, Uemura T, Ichijo T et al (2004) Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127:S17–S26PubMedCrossRef
5.
Zurück zum Zitat Stroffolini T, Andreone P, Andriulli A et al (1998) Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29:944–953PubMedCrossRef Stroffolini T, Andreone P, Andriulli A et al (1998) Characteristics of hepatocellular carcinoma in Italy. J Hepatol 29:944–953PubMedCrossRef
6.
Zurück zum Zitat Cho SJ, Yoon JH, Hwang SS et al (2007) Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 22:1226–1231PubMedCrossRef Cho SJ, Yoon JH, Hwang SS et al (2007) Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol 22:1226–1231PubMedCrossRef
7.
Zurück zum Zitat Chen CH, Chang TT, Cheng KS et al (2006) Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 26:766–773PubMedCrossRef Chen CH, Chang TT, Cheng KS et al (2006) Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver Int 26:766–773PubMedCrossRef
8.
Zurück zum Zitat Aramaki M, Kawano K, Sasaki A et al (2005) Hepatocellular carcinoma in young adults. Hepatogastroenterology 52:1795–1797PubMed Aramaki M, Kawano K, Sasaki A et al (2005) Hepatocellular carcinoma in young adults. Hepatogastroenterology 52:1795–1797PubMed
9.
Zurück zum Zitat Yamazaki Y, Kakizaki S, Sohara N et al (2007) Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci 52:1103–1107PubMedCrossRef Yamazaki Y, Kakizaki S, Sohara N et al (2007) Hepatocellular carcinoma in young adults: the clinical characteristics, prognosis, and findings of a patient survival analysis. Dig Dis Sci 52:1103–1107PubMedCrossRef
10.
Zurück zum Zitat Ng IO, Ng MM, Lai EC et al (1996) Pathologic features and patient survival in hepatocellular carcinoma in relation to age. J Surg Oncol 61:134–137PubMedCrossRef Ng IO, Ng MM, Lai EC et al (1996) Pathologic features and patient survival in hepatocellular carcinoma in relation to age. J Surg Oncol 61:134–137PubMedCrossRef
11.
Zurück zum Zitat Lam CM, Chan AO, Ho P et al (2004) Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients—implications for screening. Aliment Pharmacol Ther 19:771–777PubMedCrossRef Lam CM, Chan AO, Ho P et al (2004) Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients—implications for screening. Aliment Pharmacol Ther 19:771–777PubMedCrossRef
12.
Zurück zum Zitat Chang PE, Ong WC, Lui HF et al (2008) Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol 43:881–888PubMedCrossRef Chang PE, Ong WC, Lui HF et al (2008) Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome. J Gastroenterol 43:881–888PubMedCrossRef
13.
Zurück zum Zitat Shimada M, Takenaka K, Fujiwara Y et al (1998) Risk factors linked to postoperative morbidity in patients with hepatocellularcarcinoma. Br J Surg 85:195–198PubMedCrossRef Shimada M, Takenaka K, Fujiwara Y et al (1998) Risk factors linked to postoperative morbidity in patients with hepatocellularcarcinoma. Br J Surg 85:195–198PubMedCrossRef
14.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCrossRef Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedCrossRef
15.
Zurück zum Zitat Lack EE, Neace C, Vawter GF (1983) Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer 52:1510–1515PubMedCrossRef Lack EE, Neace C, Vawter GF (1983) Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer 52:1510–1515PubMedCrossRef
16.
Zurück zum Zitat Liver Cancer Study Group of Japan (2003) The general rules for the clinical and pathological study of primary liver cancer. Second English edition. Kanehara, Tokyo Liver Cancer Study Group of Japan (2003) The general rules for the clinical and pathological study of primary liver cancer. Second English edition. Kanehara, Tokyo
17.
Zurück zum Zitat Bruix J, Sherman M (2005) AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedCrossRef Bruix J, Sherman M (2005) AASLD practice guideline: management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMedCrossRef
18.
Zurück zum Zitat De Bac C, Stroffolini T, Gaeta GB et al (1994) Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 20:1225–1230PubMedCrossRef De Bac C, Stroffolini T, Gaeta GB et al (1994) Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 20:1225–1230PubMedCrossRef
19.
Zurück zum Zitat Schoniger-Hekele M, Muller C, Kutilek M et al (2001) Hepatocellular carcinoma in central Europe: prognostic features and survival. Gut 48:103–109PubMedCrossRef Schoniger-Hekele M, Muller C, Kutilek M et al (2001) Hepatocellular carcinoma in central Europe: prognostic features and survival. Gut 48:103–109PubMedCrossRef
20.
Zurück zum Zitat Kew MC (1981) Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from southern Africa. Hepatology 1:366–369PubMedCrossRef Kew MC (1981) Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: evidence from southern Africa. Hepatology 1:366–369PubMedCrossRef
21.
Zurück zum Zitat Merican I, Guan R, Amarapuka D et al (2000) Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15:1356–1361PubMedCrossRef Merican I, Guan R, Amarapuka D et al (2000) Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15:1356–1361PubMedCrossRef
22.
Zurück zum Zitat Lai CL, Yuen MF (2007) The natural history of chronic hepatitis B. J Viral Hepat 14(Suppl 1):6–10PubMed Lai CL, Yuen MF (2007) The natural history of chronic hepatitis B. J Viral Hepat 14(Suppl 1):6–10PubMed
23.
Zurück zum Zitat Ko CY, Hsu HC, Shen MR et al (2008) Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 283:30919–30932PubMedCrossRef Ko CY, Hsu HC, Shen MR et al (2008) Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem 283:30919–30932PubMedCrossRef
24.
Zurück zum Zitat Agrawal S, Hofmann WK, Tidow N et al (2007) The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109:3895–3905PubMedCrossRef Agrawal S, Hofmann WK, Tidow N et al (2007) The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109:3895–3905PubMedCrossRef
25.
Zurück zum Zitat Weber A, Boger R, Vick B et al (2010) Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51:1226–1236PubMed Weber A, Boger R, Vick B et al (2010) Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51:1226–1236PubMed
26.
Zurück zum Zitat Fried M, Kalra J, Iardi CF et al (1987) Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 60:2548–2552PubMedCrossRef Fried M, Kalra J, Iardi CF et al (1987) Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 60:2548–2552PubMedCrossRef
27.
Zurück zum Zitat Guariso G, Fiorio S, Altavilla G et al (1998) Congenital absence of the portal vein associated with nodular hyperplasia of the liver and cystic dysplasia of the kidney. Eur J Paediatr 157:287–290CrossRef Guariso G, Fiorio S, Altavilla G et al (1998) Congenital absence of the portal vein associated with nodular hyperplasia of the liver and cystic dysplasia of the kidney. Eur J Paediatr 157:287–290CrossRef
28.
Zurück zum Zitat Matsuoka Y, Ohtomo K, Okubo T et al (1992) Congenital absence of the portal vein. Gastrointest Radiol 17:31–33PubMedCrossRef Matsuoka Y, Ohtomo K, Okubo T et al (1992) Congenital absence of the portal vein. Gastrointest Radiol 17:31–33PubMedCrossRef
29.
Zurück zum Zitat Bannasch P (1996) Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular and metabolic changes. Prog Liver Dis 14:161–197PubMed Bannasch P (1996) Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular and metabolic changes. Prog Liver Dis 14:161–197PubMed
30.
Zurück zum Zitat Tso PL, Bringaze WL 3rd, Dauterive AH et al (1987) Gastric carcinoma in the young. Cancer 59:1362–1365PubMedCrossRef Tso PL, Bringaze WL 3rd, Dauterive AH et al (1987) Gastric carcinoma in the young. Cancer 59:1362–1365PubMedCrossRef
31.
Zurück zum Zitat de la Monte SM, Hutchins GM, Moore GW (1988) Influence of age on the metastatic behavior of breast carcinoma. Hum Pathol 19:529–534CrossRef de la Monte SM, Hutchins GM, Moore GW (1988) Influence of age on the metastatic behavior of breast carcinoma. Hum Pathol 19:529–534CrossRef
32.
Zurück zum Zitat Theuer CP, Kurosaki T, Taylor TH et al (1998) Unique features of gastric carcinoma in the young: a population-based analysis. Cancer 83:25–33PubMedCrossRef Theuer CP, Kurosaki T, Taylor TH et al (1998) Unique features of gastric carcinoma in the young: a population-based analysis. Cancer 83:25–33PubMedCrossRef
33.
Zurück zum Zitat Msika S, Benhamiche AM, Jouve JL et al (2000) Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 36:390–396PubMedCrossRef Msika S, Benhamiche AM, Jouve JL et al (2000) Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 36:390–396PubMedCrossRef
34.
Zurück zum Zitat The Cancer of the Liver Italian Program (CLIP) investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751–755CrossRef The Cancer of the Liver Italian Program (CLIP) investigators (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751–755CrossRef
35.
Zurück zum Zitat Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef
36.
Zurück zum Zitat Huang ZQ, Xu LN, Yang T et al (2009) Hepatic resection: an analysis of the impact of operative and perioperative factors on morbidity and mortality rates in 2008 consecutive hepatectomy cases. Chin Med J 122:2268–2277PubMed Huang ZQ, Xu LN, Yang T et al (2009) Hepatic resection: an analysis of the impact of operative and perioperative factors on morbidity and mortality rates in 2008 consecutive hepatectomy cases. Chin Med J 122:2268–2277PubMed
37.
Zurück zum Zitat Shimada M, Yamashita Y, Hamatsu T et al (2000) Surgical indications for advanced hepatocellular carcinoma. Hepatogastroenterology 47:1095–1099PubMed Shimada M, Yamashita Y, Hamatsu T et al (2000) Surgical indications for advanced hepatocellular carcinoma. Hepatogastroenterology 47:1095–1099PubMed
38.
Zurück zum Zitat Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225–235PubMedCrossRef Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40:225–235PubMedCrossRef
39.
Zurück zum Zitat Taketomi A, Toshima T, Kitagawa D et al (2010) Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 17:2740–2746PubMedCrossRef Taketomi A, Toshima T, Kitagawa D et al (2010) Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 17:2740–2746PubMedCrossRef
40.
Zurück zum Zitat Yoon YS, Kim HK, Kim J et al (2010) Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 17:2795–2801PubMedCrossRef Yoon YS, Kim HK, Kim J et al (2010) Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 17:2795–2801PubMedCrossRef
41.
Zurück zum Zitat He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factor in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2720PubMedCrossRef He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factor in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2720PubMedCrossRef
Metadaten
Titel
Clinicopathological Features and Outcomes of Young Patients with Hepatocellular Carcinoma after Hepatectomy
verfasst von
Kazuki Takeishi
Ken Shirabe
Jun Muto
Takeo Toshima
Akinobu Taketomi
Yoshihiko Maehara
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 5/2011
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-1017-7

Weitere Artikel der Ausgabe 5/2011

World Journal of Surgery 5/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.